Document Detail

The effect of salmeterol and salbutamol on mediator release and skin responses in immediate and late phase allergic cutaneous reactions.
MedLine Citation:
PMID:  10563469     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Salmeterol is a long-acting beta2-agonist which in animal studies has been shown to possess anti-inflammatory effects on early (EAR) and late (LPR) phase allergic responses. PURPOSE: To evaluate the anti-inflammatory effects of intradermally injected salmeterol and salbutamol on clinical and biochemical EAR and LPR in human skin. METHODS: Measurement of wheal and flare reactions to allergen, codeine, and histamine, and LPR (induration) to allergen. Assessment of histamine and prostaglandin D2 (PGD2) release by microdialysis technique in EAR, and measurement of mediators in LPR by suction blister technique. RESULTS: Both beta2-agonists inhibited allergen-induced histamine release and wheal and flare reactions with maximum inhibition of 40-50% at 10(-6) M, a concentration which reduced PGD2 synthesis by approximately 55%. Histamine release by codeine and skin reactions to codeine and histamine were not or only marginally reduced. Salmeterol and salbutamol (10(-6) M) inhibited clinical LPR at 6 h by 71% and 48%, Except for the clinical LPR, no statistical differences were found between the two drugs on any parameters. None of the drugs inhibited levels of histamine, tryptase, myeloperoxidase, or eosinophil cationic protein in LPR. CONCLUSIONS: Salmeterol and salbutamol inhibited allergen-induced skin responses, and reduced mediator release in EAR but not LPR. In general, the anti-inflammatory effects of salmeterol did not differ from those induced by salbutamol.
L J Petersen; P S Skov
Related Documents :
14700199 - Combretastatins: from natural products to drug discovery.
9159009 - Colchicine as a novel therapeutic agent in chronic bullous dermatosis of childhood.
1180749 - Therapeutic effectiveness of fluorometholone in inflammatory keratitis.
571269 - Studies on the course and therapy of the immunological and the nonspecific iridocycliti...
19199899 - Anti-angiogenic drugs as an adjunctive therapy in the surgical treatment of diabetic re...
12717799 - Enantioseparation of some clinically used drugs by hplc using cellulose tris (3,5-dichl...
6832199 - Prajmalium bitartrate in chronic ventricular arrhythmias: comparison with disopyramide.
3678289 - Are complex partial seizures an uncommon withdrawal sign in the elderly?
12935439 - Preparation and in vitro evaluation of chitosan matrices for colonic controlled drug de...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Inflammation research : official journal of the European Histamine Research Society ... [et al.]     Volume:  48     ISSN:  1023-3830     ISO Abbreviation:  Inflamm. Res.     Publication Date:  1999 Oct 
Date Detail:
Created Date:  1999-12-08     Completed Date:  1999-12-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9508160     Medline TA:  Inflamm Res     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  527-32     Citation Subset:  IM    
Department of Clinical Physiology and Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Agonists / pharmacology,  therapeutic use
Albuterol / analogs & derivatives*,  pharmacology,  therapeutic use*
Allergens / administration & dosage,  adverse effects
Dermatitis, Allergic Contact / drug therapy,  etiology
Histamine / analysis
Inflammation Mediators / metabolism*
Prostaglandin D2 / analysis
Regression Analysis
Skin Tests
Time Factors
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Allergens; 0/Inflammation Mediators; 18559-94-9/Albuterol; 41598-07-6/Prostaglandin D2; 51-45-6/Histamine; 89365-50-4/salmeterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Binding of complement component C1q to anti-beta2 glycoprotein I antibodies from patients with antip...
Next Document:  Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase.